Januvia generics occupy 17% of market in 1yr
By Kim, Jin-Gu | translator Alice Kang
24.10.28 05:56:03
가나다라
0
Combined prescriptions for Januvia and Janumet generics in Q3 amount to KRW 5.1 billion
More than 50 companies entered the market, but quarterly earnings per company were only KRW 100 million
Contrast with Tenelia’s case, where its generics occupied 51% of the market in the first year of release
Generic versions of the DPP-4 inhibitor diabetes drug ‘Januvia (sitagliptin)’ have expanded their share to 17% within a year of its launch.
In the pharmaceutical industry, the assessment is that their penetration rate is somewhat slower compared to other DPP-4 inhibitor generics.
In fact, the generic versions of Galvus (vildagliptin) and Tenelia (teneligliptin), which went off-patent before Januvia, gained market share similar to their original versions within a year of generic launch.
Q3Prescriptions of Januvia and Janumet generics in Q3 reach KRW 5.1 billion…market share rate 17%
According to the market research institution UBIST on the 28t
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)